Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Stock Information for Athira Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athira Pharma Inc.

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Athira Pharma Announces Reverse Stock Split
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.